Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak, Takashi Nakano, Jan van Meerbeeck, Sanjay Popat, Nicholas J. Vogelzang, Federica Grosso, Rasha Aboelhassan, Marko Jakopovic, Giovanni L. Ceresoli, Paul Taylor, Francisco Orlandi, Dean A. Fennell, Silvia Novello, Arnaud Scherpereel, Kozo Kuribayashi, Susana Cedres, Jens Benn Sorensen, Nick PavlakisMartin Reck, Derek Velema, Ute von Wangenheim, Miyoung Kim, Jose Barrueco, Anne S. Tsao

Research output: Contribution to journal › Article › peer-review

128 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science